Clinical Features and Determinants of In-Hospital Mortality in Patients with Stenotrophomonas maltophilia Infections

Overview

This study evaluated clinical features and factors associated with in-hospital mortality in patients with Stenotrophomonas maltophilia infections.

Background

Stenotrophomonas maltophilia is an opportunistic pathogen known for its intrinsic multidrug resistance, particularly affecting immunocompromised or critically ill patients. This study aims to clarify the role of antimicrobial exposure and treatment appropriateness in influencing patient survival.

Data Highlights

Key Findings

• In-hospital mortality was 11.8% among patients with S. maltophilia infections.
• Non-survivors were older and had higher CCI values compared to survivors.
• Severe clinical characteristics such as septic shock and mechanical ventilation were more common in non-survivors.
• Previous carbapenem exposure did not significantly affect mortality rates.
• The appropriateness of initial empirical therapy was not independently associated with survival outcomes.
• High in vitro activity was observed for minocycline, cefoperazone/sulbactam, doxycycline, and tigecycline.

Clinical Implications

Prompt supportive care and appropriate antimicrobial selection based on local susceptibility patterns are essential for managing these complex infections.

Conclusion

The study indicates that mortality in S. maltophilia infections is influenced by various factors.

Related Resources & Content

1. Author(s)/Org, Source, Year -- Title
2. Open Forum Infectious Diseases, 2023 -- Comparison of Early and Delayed Antibiotic Treatment in Patients with Stenotrophomonas maltophilia Pneumonia: A Propensity-Matched Analysis
3. Infection, 2023 -- Factors Influencing Mortality in Pseudomonas aeruginosa Bacteraemia: The Impact of Infectious Diseases Consultation and Source Control in a Retrospective Cohort Analysis
4. Infection, 2023 -- Effective Treatment of a Newborn with Nosocomial Pneumonia Caused by Stenotrophomonas maltophilia Using Cefiderocol
5. IDSA 2026 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections
6. Cefiderocol versus standard therapy for hospital-acquired and health-care-associated Gram-negative bacterial bloodstream infection (the GAME CHANGER trial): an open-label, parallel-group, randomised trial - PubMed
7. Mortality rates and risk factors associated with mortality in patients with stenotrophomonas maltophilia primary Bacteraemia and Pneumonia - PubMed
8. IDSA 2026 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections
9. Cefiderocol versus standard therapy for hospital-acquired and health-care-associated Gram-negative bacterial bloodstream infection (the GAME CHANGER trial): an open-label, parallel-group, randomised trial - PubMed
10. Mortality rates and risk factors associated with mortality in patients with stenotrophomonas maltophilia primary Bacteraemia and Pneumonia - PubMed